Prostaglandin (PG) D 2 acts through both the DP 1 receptor, which is coupled to adenylyl cyclase, and the DP 2 receptor (chemoattractant receptor-homologous molecule expressed on Th2 cells), which is present on eosinophils, basophils, and Th2 cells and results in cell activation and migration. The most potent prostanoid DP 2 agonist so far reported is 15R-methyl-PGD 2 , in which the hydroxyl group has the unnatural R configuration. In contrast, the corresponding analog possessing the natural 15S configuration is ϳ75 times less potent. This raised the question of whether the isoprostane 15R-PGD 2 might have potent DP 2 receptor-mediated biological activity. We therefore chemically synthesized 15R-PGD 2 and investigated its biological activity. This compound elicited DP 2 receptor-mediated CD11b expression in human basophils and eosinophils and induced actin polymerization and migration in eosinophils with a potency about the same as that of PGD 2 . In contrast, it had only a weak effect on DP 1 receptor-mediated adenylyl cyclase activity in human platelets. We also investigated the effects of modification of the 9-hydroxyl and 11-oxo groups of PGD 2 . Both PGK 2 , in which the 9-hydroxyl group is replaced by an oxo group, and 11-deoxy-11-methylene PGD 2 , in which the 11-oxo group is replaced by a CH 2 group, have little or no DP 1 or DP 2 agonist activity. However, the 11-methylene analog is a DP 2 antagonist (IC 50 , ϳ2 M). We conclude that 15R-PGD 2 , which may be generated by oxidative stress, is a potent and selective DP 2 agonist and that modification of the 11-oxo group of PGD 2 can result in DP 2 antagonist activity.
Prostaglandins (PGs) are formed by the action of cyclooxygenases on arachidonic acid, resulting in the addition of oxygen at positions 9, 11, and 15. The 15-hydroxyl group of enzymatically formed PGs is almost exclusively in the S configuration (Schneider et al., 2002) , an interesting exception to this being 15R-hydroxy-5,8,11,13-eicosatetraenoic acid, which is formed by aspirin-inhibited cyclooxygenase-2 (Lecomte et al., 1994) . However, isoprostanes, formed by the nonenzymatic autoxidation of arachidonic acid, are a mixture of stereoisomers, including those containing 15R-hydroxyl groups (Montuschi et al., 2004) . Prostanoids act through a series of highly selective receptors, including an eight-member family of receptors selective for PGD 2 (DP 1 receptor), PGE 2 (EP 1-4 receptors), PGF 2␣ (FP receptor), PGI 2 (IP receptor), and thromboxane A 2 (TP receptor) (Narumiya and FitzGerald, 2001) . These receptors distinguish different PGs from one another principally on the basis of the nature of the hydroxyl or keto groups at positions 9, 11, and 15. The presence of a hydroxyl group in the S configuration at C 15 is critical for optimal activation of all of the above receptors (Main and Whittle, 1975; Powell et al., 1975; Miller and Sutton, 1976) , and its oxidation by 15-hydroxy-PG dehydrogenase results in termination of biological activity (Tai et al., 2002) .
We (Monneret et al., 2001 ) and others (Hirai et al., 2001 ) recently discovered another PG receptor (the DP 2 receptor or chemoattractant receptor-homologous molecule expressed on Th2 cells) that is associated with a variety of responses in eosinophils, including calcium mobilization (Monneret et al., 2002) , actin polymerization CD11b expression, L-selectin shedding, and cell migration (Monneret et al., 2001 ). This receptor is highly selective for PGD 2 over any of the other prostanoids mentioned above. However, in contrast to other prostanoid receptors, it is activated by the PGD 2 metabolite 15-keto-13,14-dihydro-PGD 2 , in which the 15S-hydroxyl group has been oxidized (Gervais et al., 2001; Hirai et al., 2001; Monneret et al., 2001) . The sequence of the DP 2 receptor is considerably different from those of the closely related family of classic prostanoid receptors and bears much more resemblance to receptors for chemoattractants such as leukotriene B 4 (Hirai et al., 2001) , which may explain its different pattern of selectivity. Certain other modifications of the alkyl side chain (C 13 -C 20 ) of PGD 2 are also well tolerated by the DP 2 receptor, including complete removal of the C 15 hydroxyl group and rearrangement of the ⌬ 13 -double bond as in 15-deoxy-⌬ 12,14 -PGD 2 , which is equipotent with PGD 2 in activating eosinophils (Monneret et al., 2002) .
We recently identified 15R-methyl-PGD 2 as the most potent DP 2 receptor agonist yet reported (Monneret et al., 2003) . This compound is about 5 times more potent than PGD 2 and about 75 times more potent than 15S-methyl-PGD 2 , which bears the natural S configuration at C 15 . Although neither of these 15-methyl analogs is a potent agonist of the DP 1 receptor, which is associated with activation of adenylyl cyclase, 15S-methyl-PGD 2 is several times more active than the corresponding 15R isomer. The high activity of 15R-methyl-PGD 2 at the DP 2 receptor was unexpected and immediately raised the question as to whether 15R-PGD 2 , which lacks the 15-methyl group, might be a potent activator of this receptor, perhaps even considerably more potent than PGD 2 itself. This is an important issue in view of the mounting evidence for a critical role for PGD 2 and its receptors in asthma and other allergic diseases (Kostenis and Ulven, 2006) . Furthermore, 15R-PGD 2 may be formed in vivo along with other isoprostanes, as a result of oxidative stress, which is prominent in inflammatory diseases such as asthma (Caramori and Papi, 2004) . To evaluate the biological activity of 15R-PGD 2 , we prepared this substance by total chemical synthesis and investigated its ability to activate a number of DP 2 receptor-mediated responses in eosinophils and basophils as well as DP 1 receptor-mediated cAMP formation in platelets. We also tested the biological effects of other PGD 2 analogs in which the 9-and 11-hydroxyl groups were modified (Fig. 1 ).
Materials and Methods
Materials. PGD 2 , PGK 2 , 11-deoxy-11-methylene PGD 2 (11-CH 2 -PGD 2 ), 15R-methyl-PGD 2 , and 15-deoxy-⌬ 12,14 -PGD 2 were purchased from Cayman Chemical (Ann Arbor, MI). 15R-PGD 2 was prepared by total chemical synthesis as described previously (Kim et al., 2005) . Reagents used for staining cells for flow cytometry were as follows: N- (7-nitrobenz-2-oxa-1,3-diazol-4-yl Analysis of CD11b Expression in Eosinophils and Basophils. CD11b expression on eosinophils and basophils was measured in whole blood from healthy human subjects, following the removal of plasma as described previously (Monneret et al., 2005) . Blood from healthy volunteers, collected using citrate as the anticoagulant, was diluted with 5 volumes of phosphate-buffered saline (PBS), centrifuged, and the pellet was resuspended to the original volume in PBS containing CaCl 2 (1.8 mM) and MgCl 2 (1 mM). The cells were preincubated at 37°C for 5 min, followed by incubation with either vehicle (10 l of PBS containing 0.1% BSA) or prostaglandins for 10 min. After termination of the incubations with icecold FACSFlow (2 ml; Becton-Dickinson), the tubes were centrifuged, and the pellets were incubated for 30 min at 4°C with a mixture of FITC-labeled anti-IgE, PE-labeled anti-CD11b, and PC5-labeled anti-CD49d in PBS. Red cells were then lysed with Optilyse C (Beckman-Coulter; 15 min at 23°C). The cells were centrifuged and resuspended in PBS containing 1% formaldehyde. The distribution of fluorescence intensities was measured by flow cytometry using a FACSCalibur instrument (Becton-Dickinson) using WinMDI software for data analysis. Eosinophils and basophils were identified on the basis of intense labeling with anti-CD49d and anti-IgE, respectively, along with side and forward scatter.
In experiments in which CD11b was measured in eosinophils alone, mixed leukocytes were prepared as described above. Aliquots (0.5 ml; 10 6 cells/ml) were preincubated for 5 min at 37°C and then for a further for 10 min with agonists. The incubations were terminated by addition of ice-cold FACSFlow and centrifugation. The cells were then stained with a mixture of PE-labeled anti-CD49d and FITC-labeled anti-CD11b and treated with Optilyse and formaldehyde as described previously (Monneret et al., 2002) . CD11b expression was measured in eosinophils (high CD49d, high side scatter, low forward scatter) by flow cytometry.
Measurement of Actin Polymerization in Eosinophils. Actin polymerization was measured in a mixed leukocyte fraction obtained by treatment of whole blood with Dextran T-500 for 45 min at 4°C, followed by hypotonic lysis as described previously (Monneret et al., 2002) . Leukocytes were prelabeled with PC5-labeled mouse antihuman CD16 for 30 min on ice. After washing by centrifugation the cells were resuspended in PBS (137 mM NaCl, 2.7 mM KCl, 1.5 mM KH 2 PO 4 , and 8.1 mM Na 2 HPO 4 , pH 7.4) containing Ca 2ϩ (1.8 mM) and Mg 2ϩ (1 mM). Aliquots of the leukocyte suspension (90 l, 5 ϫ 10 6 cells/ml) were preincubated for 5 min at 37°C followed by the addition of either vehicle (10 l of PBS containing 0.1% BSA) or prostaglandins. After 20 s, the incubations were terminated by the addition of formaldehyde (final concentration, 8.5%), and the samples were kept on ice for 30 min. Cytosolic F-actin was stained by incubation with a mixture of lysophosphatidylcholine (30 g in 23.8 l of PBS) and N- (7-nitrobenz-2-oxa-1,3-diazol-4-yl) -phallacidin (49 pmol in 6.2 l of methanol; final concentration, 0.3 M) overnight in the dark at 4°C. The cells were then washed by centrifugation and resuspended in 300 l of PBS containing 1% formaldehyde. F-actin levels were measured by flow cytometry in eosinophils, which were identified on the basis of high side scatter and low CD16 expression.
Evaluation of Eosinophil Migration. Eosinophil migration was measured as described previously (Monneret et al., 2001 ) by means of 48-well microchemotaxis chambers (Neuro Probe, Cabin John, MD) and Sartorius cellulose nitrate filters (8-mm pore size; 140-mm thickness) (Neuro Probe). PGs were added to the bottom well in a volume of 30 l of PBS containing 1.8 mM CaCl 2 , 1 mM MgCl 2 , and 0.3% bovine serum albumin, whereas eosinophils or neutrophils (150 000 cells in 55 l of RPMI containing 0.4% ovalbumin) were added to each of the top wells. Following incubation for 2 h at 37°C, the filters were fixed with mercuric chloride and stained with hematoxylin and chromotrope 2R (Kay, 1970) . The numbers of cells on the bottom surfaces of the filters were counted in five different fields at a magnification of 400ϫ for each incubation, each of which was performed in duplicate.
Determination of cAMP Levels in Platelets. Platelets were prepared from whole blood obtained from healthy volunteers as described previously (Monneret et al., 2003) . After washing by centrifugation, they were resuspended in PBS containing Ca 2ϩ (1.8 mM) and Mg 2ϩ (1 mM) to give a concentration of 3 ϫ 10 8 platelets/ml. Aliquots (100 l) of this suspension were preincubated for 2 min at 37°C with isobutylmethylxanthine (1 mM) and then incubated for a further 2 min with either vehicle (10 l of PBS containing 0.1% BSA) or prostaglandins. The incubations were terminated by the addition of ice-cold ethanol (300 l), and the precipitated proteins were removed by centrifugation (600g for 15 min). cAMP in the supernatants was measured using a competitive protein-binding radiometric assay (Diagnostic Products, Los Angeles, CA) according to the manufacturer's instructions.
Data Analysis. The statistical significance of differences between means was determined using either analysis of variance with the Bonferroni test as a multiple comparison method or Student's t test as appropriate. EC 50 and IC 50 values are the means Ϯ S.E. of values obtained from "n" individual experiments.
Results

15R-PGD 2 Elicits CD11b Expression by Eosinophils and Basophils.
We examined the effect of 15R-PGD 2 , PGD 2 , and 15R-methyl-PGD 2 on CD11b expression by human eosinophils using whole blood from which the plasma had been removed ( Fig. 2A) . 15R-PGD 2 (EC 50 , 0.5 Ϯ 0.1 nM) and 15R-methyl-PGD 2 (EC 50 , 0.5 Ϯ 0.25 nM) appeared to be slightly more potent than PGD 2 (EC 50 , 1.2 Ϯ 0.5 nM) in stimulating CD11b expression, but these differences were not statistically significant. We also measured the effects of these compounds on CD11b expression in basophils in the same blood samples and obtained essentially similar results, although the EC 50 values tended to be slightly higher in basophils compared with eosinophils (Fig. 2B) . The potencies of the three compounds were in the order: 15R-methyl-PGD 2 (EC 50 , 1.3 Ϯ 0.6 nM) Ͼ 15R-PGD 2 (EC 50 , 3.9 Ϯ 2.8 nM) Ͼ PGD 2 (EC 50 , 5.6 Ϯ 3.1 nM), but these differences were not statistically significant.
15R-PGD 2 Is a Potent Stimulator of Actin Polymerization in Eosinophils. The effect of 15R-PGD 2 on actin polymerization in eosinophils was determined by flow cytometry using a preparation of mixed leukocytes (Fig. 3) . The concentration-response curve for 15R-PGD 2 (EC 50 , 12 Ϯ 5 nM) was virtually identical to that for PGD 2 (EC 50 , 19 Ϯ 8 nM). The potencies of both substances for actin polymerization were about 10 times lower than for CD11b expression, perhaps due to the shorter time of the assay. The actin response to PGD 2 in eosinophils is very rapid, peaking after 20 s and then diminishing, whereas agonist-induced CD11b expression rises much more slowly and plateaus by 10 min (Monneret et al., 2002) .
15R-PGD 2 Promotes Eosinophil Migration. We investigated the effect of 15R-PGD 2 on eosinophil migration using eosinophils purified by positive immunomagnetic selection (Fig. 4) . As with the other responses, the potency of 15R-PGD 2 (EC 50 , 2 Ϯ 0.5 nM) was very similar to that of PGD 2 (EC 50 , 4 Ϯ 2.4 nM). However, the maximal response to PGD 2 (57 Ϯ 6 cells/high-power field) was somewhat greater than that to 15R-PGD 2 (44 Ϯ 6 cells/high-power field) (P Ͻ 0.005).
Effects of 15R-PGD 2 on cAMP Formation by Platelets. To determine whether 15R-PGD 2 is selective for DP 2 receptors, we investigated its effect on cAMP formation in human platelets (Fig. 5) . Compared with PGD 2 (EC 50 , 79 Ϯ 11 nM), 15R-PGD 2 is a very weak stimulator of DP 1 receptormediated cAMP formation. Although the maximal response to 15R-PGD 2 was not achieved at the highest concentration tested (10 M), this concentration gave rise to a response that was only about 50% that to a 100 times lower concen- Effects of Modification of the 9-and 11-Substituents of PGD 2 on DP 1 and DP 2 Receptor-Mediated Responses. We also investigated the effects of oxidation of the C 9 hydroxyl group of PGD 2 to an oxo group (i.e., PGK 2 ) and replacement of the C 11 oxo group by a methylene group (i.e., 11-CH 2 -PGD 2 ) on PGD 2 receptor-mediated responses in eosinophils and platelets. PGK 2 did not elicit either CD11b expression (Fig. 6A) or actin polymerization (Fig. 6B) in eosinophils, whereas 11-CH 2 -PGD 2 appeared to have a slight stimulatory effect on CD11b expression at the highest concentration (10 M) tested (P Ͻ 0.005). Although both 11-CH 2 -PGD 2 and PGK 2 had significant stimulatory effects on cAMP formation by platelets (P Ͻ 0.001; Fig. 6C ) at the highest concentration tested (10 M), these responses were only about 5% of the maximal response to PGD 2 . Thus, these two substances have very little agonist activity on both DP 1 and DP 2 receptors.
Antagonistic Effects of 11-CH 2 -PGD 2 and PGK 2 on DP 2 Receptor-Mediated Responses. We investigated whether 11-CH 2 -PGD 2 and PGK 2 could antagonize the responses to DP 2 receptor agonists in eosinophils. 11-CH 2 -PGD 2 nearly completely blocked the effect of the selective DP 2 receptor agonist 15-deoxy-⌬ 12,14 -PGD 2 on CD11b expression in eosinophils with an IC 50 value of 2.8 Ϯ 1.3 M (Fig. 7A) . PGK 2 had a similar effect but was less potent, with about 50% inhibition being achieved at the highest concentration tested (10 M). 11-CH 2 -PGD 2 had a similar effect on PGD 2 -mediated actin polymerization in eosinophils, inhibiting this response with an IC 50 of 1.7 Ϯ 0.9 M (Fig. 7B) . In contrast, 11-CH 2 -PGD 2 had no effect on 5-oxo-6,8,11,14-eicosatetraenoic acid-induced actin polymerization in these cells (data not shown).
To determine whether 11-CH 2 -PGD 2 also inhibits DP 1 -mediated responses, its effects on PGD 2 -induced cAMP formation in platelets were investigated. At the highest concentration tested (10 M), 11-CH 2 -PGD 2 inhibited the response to PGD 2 (100 nM) by 44% (Fig. 7C) . The same degree of inhibition of DP 2 -mediated responses by 11-CH 2 -PGD 2 in eosinophils was achieved at lower concentrations, and actin polymerization and CD11b expression were inhibited by 44% by concentrations of 1 and 2 M, respectively.
Discussion
The present study was prompted by our recent finding that 15R-methyl-PGD 2 , in which the C 15 hydroxyl group is in the unnatural R configuration, is a much more potent DP 2 receptor agonist than its 15S-methyl counterpart, in which the C 15 hydroxyl group has the same configuration as in PGD 2 (Monneret et al., 2003) . This was surprising because PGs with 15R hydroxyl groups normally display little biological activity (Main and Whittle, 1975; Powell et al., 1975; Miller and Sutton, 1976) and raised the question of whether 15R-PGD 2 itself, without the additional methyl group, might be a potent DP 2 receptor agonist, perhaps even more potent than PGD 2 itself. To investigate the ability of 15R-PGD 2 to activate DP 2 receptor-mediated responses, this compound was prepared by total chemical synthesis (Kim et al., 2005) . We then evaluated the ability of 15R-PGD 2 to stimulate DP 2 receptormediated responses in eosinophils, including actin polymerization, which is associated with cell movement, expression of CD11b, an adhesion molecule that is required for migration 5 . Effects of 15R-PGD 2 on cAMP levels in platelets. Human platelets were preincubated for 2 min with isobutylmethylxanthine (1 mM) and then incubated for a further 2 min with various concentrations of 15R-PGD 2 (F), PGD 2 (E), or 15R-methyl-PGD 2 (15Me; ‚). cAMP in the supernatants was measured using a competitive protein-binding radiometric assay as described under Materials and Methods. All values are means Ϯ S.E. (n ϭ 4). of granulocytes through the endothelium, and cell migration. To determine the activity of 15R-PGD 2 at the DP 1 receptor, we investigated its effects on cAMP formation in platelets, which highly express this receptor. 15R-PGD 2 was found to be approximately equipotent with PGD 2 in stimulating all of the DP 2 receptor-mediated responses in eosinophils. 15R-PGD 2 also strongly stimulated CD11b expression in basophils, which highly express both DP 1 and DP 2 receptors (Hirai et al., 2001) . In contrast, it is between 2 and 3 orders of magnitude less potent than PGD 2 in stimulating DP 1 receptor-mediated cAMP formation in platelets.
In addition to inversion of the stereochemistry of the 15S-hydroxyl group of PGD 2 , various other modifications of the substituents at C 15 of PGD 2 have little effect on DP 2 -mediated responses. For example, oxidation of the hydroxyl group to a keto group, as in 13,14-dihydro-15-keto-PGD 2 , only slightly reduces DP 2 agonist activity but completely abolishes DP 1 agonist activity (Gervais et al., 2001; Hirai et al., 2001; Monneret et al., 2001) . Likewise, removal of the 15-hydroxyl group coupled with the addition of a double bond to the alkyl side chain of PGD 2 (15-deoxy-⌬ 12,14 -PGD 2 ) does not affect DP 2 activity (Monneret et al., 2002) but dramatically reduces DP 1 -mediated responses (Bundy et al., 1983 ). As noted above, inversion of the stereochemistry at C 15 coupled with addition of a methyl group increases potency at the DP 2 receptor and nearly completely eliminates it at the DP 1 receptor (Monneret et al., 2003) . These findings might be interpreted to suggest that the alkyl side chain of PGD 2 does not play a role in DP 2 receptor-mediated activity. However, in contrast to the above modifications, addition of a methyl group to PGD 2 , without alteration of the configuration at C 15 (15S-methyl-PGD 2 ), results in an over 10-fold loss in potency at the DP 2 receptor (Monneret et al., 2003) . This suggests that the alkyl side chain is required for full DP 2 agonist activity, perhaps due to a hydrophobic interaction with the receptor, because the hydroxyl group itself is not required for activity (Monneret et al., 2002) . It is possible that addition of a methyl group to PGD 2 places the 15S-hydroxyl group in a position that interferes sterically with this interaction, whereas the hydroxyl group in the 15R-methylhydroxy analog does not have this effect.
In contrast to the DP 2 receptor, the 15S-hydroxyl group of PGD 2 is clearly required for activation of the DP 1 receptor because its removal (15-deoxy-⌬ 12,14 -PGD 2 ), oxidation (13,14-dihydro-15-keto-PGD 2 ), addition of a methyl group (Powell, 2003) , or inversion (15R-PGD 2 ) all nearly abolish agonist activity at this receptor. This suggests that unlike the DP 2 receptor, there must be a strong hydrophilic interaction between the hydroxyl group of the alkyl side chain of PGD 2 and the DP 1 receptor.
The strong DP 2 agonist activity of 15R-PGD 2 may have biological implications because this compound could be formed in vivo as a result of autoxidation of arachidonic acid. This process gives rise to a large number of isoprostanes, some of which are identical to enzymatically generated prostaglandins (Rokach et al., 2004) . It has been shown that in addition to enzymatically generated PGD 2 , large amounts of racemic PGD 2 , presumably synthesized by a free radical process, are formed as a result of subjection of rats to oxidative stress in vivo. Ent-PGD 2 was detected in significant amounts in both rat and human urine under basal conditions and increased to about 35 times control levels in response to oxidative stress induced by administration of carbon tetrachloride to rats (Gao et al., 2003) . Although no attempt to Fig. 6 . Effects of 11-CH 2 -PGD 2 and PGK 2 on DP 2 and DP 1 receptor-mediated responses in eosinophils and platelets. Unfractionated leukocytes (A and B) or platelets (C) were incubated with PGD 2 (F), 11-CH 2 -PGD 2 (E), or PGK 2 (K 2 ; OE). CD11b (A) and F-actin (B) were measured by flow cytometry, whereas cAMP was measured using a protein binding assay as described under Materials and Methods. All values are means Ϯ S.E. For A and B, n ϭ 5 (PGD 2 ), 4 (11-CH 2 -PGD 2 ), or 3 (PGK 2 ). For C, n ϭ 4. Fig. 7 . Inhibitory effects of 11-CH 2 -PGD 2 and PGK 2 on DP 2 and DP 1 receptor-mediated responses in eosinophils and platelets. Leukocytes (A and B) or platelets (C) were preincubated for 5 min with different concentrations of 11-CH 2 -PGD 2 (F) or PGK 2 (E). A, leukocytes were incubated for a further 10 min with 15-deoxy-⌬ 12,14 -PGD 2 (10 nM), and CD11b was measured by flow cytometry as described under Materials and Methods. B, leukocytes were incubated for 20 s with PGD 2 (30 nM), and F-actin was measured by flow cytometry as described under Materials and Methods. C, platelets were incubated for a further 2 min with PGD 2 (100 nM), followed by measurement of cAMP as described under Materials and Methods. All values are means Ϯ S.E. (n ϭ 3).
Effects of 15R-PGD 2 and 11-Methylene-PGD 2 on Granulocytes 177 at ASPET Journals on April 10, 2017 jpet.aspetjournals.org Downloaded from identify 15R-PGD 2 was made in this study, it would seem likely that it would be formed along with other PGD 2 isomers under conditions of oxidative stress. The potent DP 2 agonist activity of this compound could contribute to proinflammatory responses following oxidative damage to tissues in various inflammatory diseases such as asthma.
Like the 15-hydroxyl group, the 9-hydroxyl group of PGD 2 is not a requirement for activation of DP 2 receptors. PGJ 2 , which lacks this hydroxyl group, has about one-fifth the potency of PGD 2 , whereas 15-deoxy-⌬ 12,14 -PGJ 2 , which lacks both the 9-and 15-hydroxyl groups, is equipotent with PGD 2 (Monneret et al., 2002) . Neither does activation of the DP 1 receptor require the 9-hydroxyl group because PGJ 2 is equipotent with PGD 2 in stimulating DP 1 receptor-mediated elevation of cAMP levels in platelets (Wright et al., 1998) . However, it would seem that this part of the molecule does play some role in activation of the DP 2 receptor by PGD 2 because the present study demonstrates that oxidation of the 9-hydroxyl group to an oxo group, as in PGK 2 , abolishes agonist activity and results in a small degree of antagonist activity.
The 11-oxo group of PGD 2 is clearly critical for activation of both the DP 1 and DP 2 receptors. We have shown that reduction of this group to a hydroxyl group (11␤-PGF 2␣ ) results in a 100-fold reduction in potency at the DP 2 receptor (Monneret et al., 2002) , and it has been shown by others (Giles et al., 1991 ) that this modification results in an approximately 50-fold reduction in DP 1 -mediated activity. The importance of this oxo group is confirmed by the present study because 11-CH 2 -PGD 2 has little or no agonist activity on both DP 1 and DP 2 receptors. In contrast, 11-CH 2 -PGD 2 has antagonist activity at the DP 2 receptor, inhibiting both DP 2 -mediated CD11b expression and actin polymerization in eosinophils by about 80% at a concentration of 10 M and having an IC 50 of about 2 M. PGK 2 also has antagonist activity but is less potent, exhibiting about 50% inhibition of DP 2 receptor-mediated CD11b expression at a concentration of 10 M. 11-CH 2 -PGD 2 also has some antagonist activity at the DP 1 receptor but is less potent because it inhibited PGD 2 -induced cAMP formation in platelets by less than 50% at a concentration of 10 M.
Although the present study is the first to identify a PGD 2 analog with DP 2 receptor antagonist activity, a number of nonprostanoids have been demonstrated to be fairly potent DP 2 antagonists. The finding that indomethacin, in addition to its potent cyclooxygenase inhibitory activity, is also a DP 2 receptor agonist (Hirai et al., 2002) led to a search for other indolic compounds that might have antagonist activity. The first DP 2 antagonist to be identified was ramatroban (IC 50 approximately 100 nM) (Sugimoto et al., 2003) , which is an indolic compound that was originally developed by Bayer as a selective TP receptor antagonist (Theis et al., 1992) . Minor structural modification of ramatroban resulted in a highly selective and potent DP 2 antagonist (Ulven and Kostenis, 2005) . Other indolic compounds with selective DP 2 receptor antagonist activities have also recently been reported (Armer et al., 2005; Birkinshaw et al., 2006) . A series of tetrahydroquinoline derivatives have also been identified as selective DP 2 antagonists (Mimura et al., 2005) .
In conclusion, 15R-PGD 2 is a potent and selective DP 2 receptor agonist. It is equipotent to PGD 2 in stimulating a variety of responses in eosinophils and basophils but has very little DP 1 receptor-mediated activity in platelets. Replacement of the 11-oxo group of PGD 2 by a methylene group resulted in conversion of agonist to antagonist activity at the DP 2 receptor, a finding that may be useful in the design of future DP 2 receptor antagonists.
